FDA Tentatively Approves Generic PRRT Lutetium Lu 177 Dotatate (177Lu-PNT2003) in GEP-NETs (plus news of a new SSTR PET!)

FDA Tentatively Approves Generic PRRT Lutetium Lu 177 Dotatate (177Lu-PNT2003) in GEP-NETs (plus news of a new SSTR PET!)

We have generic somatostatin analogues, generic targeted therapy e.g. Afinitor, and I guess it was only a matter of time until we got generic PRRT (Radioligand Therapy) e.g. generic Lutetium Lu177 dotatate.  This news begins that process which is also based on a clinical trial which took place in Canada (195 participants) and which now appears to be complete.  The announcement comes from US but if this is realised, you can expect it to be available in many other countries and continents where there is a market.  This may even drive down prices and/or increase availability.  "PNT2003: The First Radioequivalent…
Read More
Generic Somatostatin Analogues for Neuroendocrine Cancer

Generic Somatostatin Analogues for Neuroendocrine Cancer

Generic Somatostatin Analogues.   I've covered a lot about somatostatin analogues, particularly the two predominant approved drugs Lanreotide and Octreotide.  Octreotide has many particularly in daily shots and more recently in long acting, but Lanreotide being a newer drug has taken a while for generics to appear.  I had to study what generic means and it's important to differentiated the brand from the actual drug name as the latter does not normally change. The reason for publication of this blog is because I was concerned to hear patients asking questions about generic lanreotide and octreotide in my private Facebook group where they…
Read More
Somatostatin Analogues and delivery methods in the pipeline

Somatostatin Analogues and delivery methods in the pipeline

NOTE - THIS IS IN NEED OF AN UPDATE AND IS ON MY LIST OF THINGS TO DOThis is my live blog post covering new developments in the area of new Somatostatin Analogues and new delivery systems. AbstractAs most of you will be aware, there are currently two main types of Somatostatin Analogues (SSA) in use for the treatment of mainstream Neuroendocrine Tumours (NETs) - Octreotide and Lanreotide.  You can click on the links for information on both of these well-known NET treatments.  This post will focus on the not so well known and anything in the pipeline including different delivery…
Read More